Skip to search formSkip to main contentSkip to account menu

Ly-2127399

Known as: LY2127399, LY3022859 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

tabalumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors
PurposeLY3022859 is an anti-TGFβRII IgG1 monoclonal antibody that inhibits receptor-mediated signaling activation. The primary… 
2016
2016
Dose‐escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma
B‐cell activating factor (BAFF) promotes the survival and adhesion of multiple myeloma (MM) cells. Tabalumab (LY2127399) is an… 
Review
2015
Review
2015
Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) comprises several clinical entities with diverse clinical… 
Review
2013
Review
2013
Treating multiple sclerosis with monoclonal antibodies: a 2013 update
The third part of this in-depth review series on the treatment of multiple sclerosis (MS) with monoclonal antibodies covers the… 
2013
2013
SAT0005 Human C-Type Lectin Domain Family 4, Member C Gene Expression Level Helps Predict Future Clinical Response to Tabalumab Blockade of Baff in Rheumatoid Arthritis
Background Patients with rheumatoid arthritis (RA) exhibit substantial variability in both the magnitude and duration of their… 
Review
2012
Review
2012
Biologic Differences Between Various Inhibitors of the BLyS/BAFF Pathway: Should We Expect Differences Between Belimumab and Other Inhibitors in Development?
  • W. Stohl
  • Current Rheumatology Reports
  • 2012
  • Corpus ID: 42980394
For the first time in more than 50 years, the US Food and Drug Administration has approved a drug specifically for the treatment… 
2011
2011
Phase I study of LY2127399, a human anti-BAFF antibody, and bortezomib in patients with previously treated multiple myeloma.
8012 Background: LY2127399 (LY) is a human mAb that neutralizes membrane-bound and soluble B cell activating factor (BAFF). LY… 
Review
2011
Review
2011
Targeting Bone as a Therapy for Myeloma
Myeloma bone disease (BD) not only impairs quality of life, but is also associated with impaired survival. Studies of the biology… 
Review
2010
Review
2010
Treating multiple sclerosis with monoclonal antibodies: a 2010 update
  • M. Buttmann
  • Expert Review of Neurotherapeutics
  • 2010
  • Corpus ID: 24588796
Treating multiple sclerosis (MS) with monoclonal antibodies (mAbs) has been marked by both progress and setbacks in the past 2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)